Setting new standards in validation
Every recombinant antibody produced at Abcam undergoes rigorous testing to ensure appropriate specificity, sensitivity, and overall performance related to its application.
While our in-house antibody validation incorporates several advanced technologies a central element of our programme includes the routine use of knockout (KO) validation that employs CRISPR gene-edited KO cell lines to provide “true” negative controls.
This initiative was recognised with a 2020 CiteAb award for KO validation.
The specificity of more than 2500 Abcam recombinant antibodies has been validated using KO validation – an unprecedented scale within the industry.
In addition, we have expanded KO validation beyond our own in-house product manufacturing. By launching a wide range of over 2,800 ready-to-use, off-the-shelf gene-edited KO cell lines, and lysates, we are enabling researchers to KO validate their antibodies in their own specific systems. This is encouraging researchers to confidently carry out their own antibody validation – without the time-consuming need to first establish a specific KO cell line.
We are committed to data transparency and all our antibodies are supported with extensive information, validation and scientific insight.